HYPOGAMMAGLOBULINEMIA
Clinical trials for HYPOGAMMAGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new HYPOGAMMAGLOBULINEMIA trials appear
Sign up with your email to follow new studies for HYPOGAMMAGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New shot aims to shield myeloma patients from infections
Disease control Recruiting nowThis study tests whether a drug called IgPro20 can reduce infections in people with multiple myeloma who have low antibody levels due to bispecific antibody treatment. About 100 participants will either receive IgPro20 or standard care, and infection rates will be compared over 6…
Matched conditions: HYPOGAMMAGLOBULINEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:01 UTC
-
New drug aims to shield blood cancer patients from deadly infections
Prevention Recruiting nowThis study tests whether a medicine called XEMBIFY, given every two weeks alongside standard care, can reduce serious bacterial infections in adults with certain blood cancers (chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma) who also have low antibody lev…
Matched conditions: HYPOGAMMAGLOBULINEMIA
Phase: PHASE3 • Sponsor: Grifols Therapeutics LLC • Aim: Prevention
Last updated May 26, 2026 02:48 UTC
-
MS fatigue mystery: could low antibodies be the hidden cause?
Knowledge-focused Recruiting nowThis study looks at whether low levels of immunoglobulins (antibodies) are a treatable cause of fatigue in people with multiple sclerosis (MS). Researchers will compare fatigue levels and infection rates in 106 MS patients with and without low antibody levels. The goal is to unde…
Matched conditions: HYPOGAMMAGLOBULINEMIA
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated May 26, 2026 03:02 UTC